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ABSTRACT

Previous studies performed on Chlamydia trachomatis have demonstrated how these
obligate intracellular microbes invade host cells through the utilization of secreted effector
proteins. One secreted effector called Tarp (translocated actin recruiting protein) is implicated in
cytoskeleton rearrangements that promote bacterial entry into the host cell. The focus of our
study is to create a plasmid that carries the tarP gene that when transcribed and translated from
within Chlamydia trachomatis will generate a c-Myc epitope tagged Tarp. The tag will be used
in future studies to track the progression of the protein through the infectious process and will
allow us to distinguish this protein from the Tarp effector expressed from the endogenous wild
type gene. The epitope-tagged Tarp expression plasmid will be used as a template to construct
Tarp deletion mutants. The mutant forms will be created in regions that have been biochemically
characterized and predicted to be important to the invasion process of the pathogen. Observations
on the potential phenotypes of these mutants and the possibility of allelic exchange will also be
pursued in the future.
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INTRODUCTION
Chlamydia trachomatis LGV 2
Chlamydia trachomatis is a gram-negative, intracellular bacterium which replicates
exclusively within mammalian host cells [10]. This microorganism falls under the genus of
Chlamydia and is among one of the three major chlamydial species recognized within the
scientific

community

to

cause

human

diseases.

The

other

2

species

are

Chlamydophila pneumonia and Chlamydophila psittaci which have their pathogenicity geared
towards the respiratory systems, whereas C. trachomatis infections are more commonly found in
the reproductive and ocular systems [7, 8]. The infection may be contracted through the mucosal
membranes, smooth muscles, and epithelial cells. The severity and persistence of the infection is
partially determined by the location of the infection [9]. Details of the infectious process will be
covered later in the “Developmental Cycle and Infectious Process” section. The bacterium of
interest within this study is further broken down into biovars and serovars, which are trachoma
and LGV 2 respectively [7]. Another distinguishing characteristic of Chlamydia is that it harbors
a plasmid of 7.5 kilobase pairs and one complete developmental cycle takes approximately 48
hours in vitro. This plasmid will be the main focus of my study [6, 11].
Epidemiology

Chlamydia trachomatis is the leading cause of preventable blindness worldwide and
infertility in both males and females in the nation [1, 2]. The infection may result in severe
inflammation or remain dormant for an extended period of time. A non-discriminatory pathogen,
populations of all gender and race has an equal chance of contracting the disease. The disease is
1

most prominent among sexually active adults and among populations in less developed
communities that have a poorer standard of hygiene. Sexually active patients with chlamydial
infections are often asymptomatic, and are at risk for infertility due to infections in the
genitourinary tract. Repeated infections or chronic infection in woman can lead to pelvic
inflammatory disease (PID) and eventually infertility [1]. In the year 2010, about 1 million cases
of chlamydial infections were reported nationwide but may have been grossly underestimated
due to the absence of symptoms in people who are infected. The greatest occurrence of infection
is observed in the African American and Native American populations. Chlamydia is the most
common type of bacterial sexually transmitted infections (STI) within the United States and
Japan [13].
Developmental Cycle and Infectious Process

Figure 1. The Developmental Life Cycle of Chlamydia trachomatis.
The bacterium first makes contact with the host cell in their infectious form, called elementary bodies (EB).
Once these pathogens enter through the cell membrane with the help of effector proteins, such as TARP, they
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are enclosed within a vesicle called an inclusion body. Within the inclusion body, the EBs differentiate into
their metabolically active form called reticulate bodies (RB) and begin to replicate. After several rounds, the
RBs revert back into EBs and leave the host cell through either exocytosis or cell lysis and will go on to infect
the nearby host cells.

As shown in Figure 1, the obligate intracellular prokaryote C. trachomatis is present in
one of two developmental forms. During the infectious phase, the bacteria are called the
elementary bodies (EB) and during the noninfectious phase they are called the reticulate bodies
(RB) [5]. Based on past in vitro studies, it was shown that the effector protein Tarp (translocated
actin recruiting protein) played an important role in allowing Chlamydia trachomatis to enter
host cells [3]. Tarp has 3 characterized protein domains which consist of an actin binding domain
(ABD), phosphorylation domain (PhosD), and a proline rich domain (PRD), as depicted in
Figure 2 [3, 4].

Figure 2. TARP’s ABD is specialized for G-actin and F-actin binding.
In a recent Chlamydia publication, of which I was a co-author, our lab provided evidence that TARP has a
very diverse ABD. In further TARP protein assays, it was shown that TARP caused nucleation and bundling
of different forms of actin, which includes globular and fibrous actin.
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The ABD and PRD are critical for Tarp mediated actin nucleation which is believed to be
required for invading host cells. Actin polymerization results in the formation of pseudopods
which extend around the bacterium and engulf it into the cytoplasm. Intracellular C. trachomatis
is enclosed within an endosome, called an inclusion body. Within this protective niche, the
bacterium transforms from an EB to an RB to replicate within the host cell [3]. At the end of the
developmental cycle, RBs convert back to EBs and are liberated from the host cell either through
exocytosis or cell lysis to infect new cells [5].
Chlamydia trachomatis appears to have evolved over time through a close relationship
with the eukaryotic host and consequently has acquired the ability to manipulate the host signal
transduction cascades to their benefit. Pathogenicity of the bacterium lies in the fact that they are
often shielded from the adaptive immune system of humans because of the sanctuary that they
have found in inclusion bodies. These structures allow them to evade opsonization,
neutralization, and T cell recognition. Moreover, after C. trachomatis has invaded the host cell,
they express proteins that elicit transcription factors, such as NF-κB, which signals the
recruitment of cellular proinflammatory chemokines and inhibits apoptosis of the infected cell
[9]. These elicited chemokines will cause inflammation of the infected tissues within the host
which will eventually lead to diseases previously mentioned. Since the bacterium lacks muramic
acid within the peptidoglycan cell wall, treatment with penicillin is theoretically futile. However,
when penicillin is administered, the developmental cycle comes to a halt even though the
bacteria are still viable. Stronger antibiotics, such as azithromycin, are more effective at
eliminating the infection [10].

4

Oftentimes the infection can be cleared out on its own because Chlamydia within
epithelial cells is more prone to be removed from the body when the cell undergoes the transition
phase of shedding off in order for new cells to rise to the surface. Another possibility is clearance
through the body’s adaptive immune response which has been shown to be tied to CD8+
cytotoxic T cells, IgA, IFN-γ, and TH1 CD4+ T cells. However, C. trachomatis has been shown
to manifest an immune evasion strategy which is through the expression of serovar specific
antigens within the genus and species. This diversity limits our body’s ability to develop
immunity to all Chlamydia serovars/biovars resulting in new infections or reinfections of C.
trachomatis [9].
DNA technology

Studies performed on C. trachomatis have been limited due to the absence of DNA
technology available to manipulate and experiment with the bacterial genome. Only recently, a
new protocol has been devised by the lab of Dr. Ian Clark that allows for the transformation of
DNA into Chlamydia [12].

This new breakthrough is a major stepping stone towards

understanding the functionality of different genes that may play an important role in
pathogenicity. The transformation system also allows for new genes to be introduced into the
bacteria for the first time [7].
Hypothesis: Expression of epitope tagged Tarp effector mutants from within C. trachomatis
will identify those protein domains required for bacterial entry and development.

Genetic manipulation of C. trachomatis has proven difficult, but recently a
transformation system has been developed by Dr. Ian Clark’s lab to transform foreign DNA into
5

the bacteria. The goal of this study is focused on using this new technology to express epitope
tagged genes in C. trachomatis [12].
In addition, shuttle vectors have been created in my past experiments which will enable
for chlamydial and foreign genes to be expressed in both E. coli and C. trachomatis with ease.
The genes transformed into these bacteria allows for it to be selected through resistance to a
specific antibiotic. The application of this method will be further elaborated in the sections to
come.

6

PURPOSE
The primary focus of my study is on the creation of a plasmid that will carry the genetic
sequence that expresses the C. trachomatis Tarp effector. In order to distinguish between the
endogenous Tarp expressed on the bacterial chromosome and the Tarp from the plasmid, Tarp
will be engineered with an epitope tag that can be detected with monoclonal antibodies. The
significance of this study lies in the fact that the expression of epitope tagged C. trachomatis
effectors has never been pursued before because a transformation system for this prokaryote was
not present until recently. If shown to be successful, this project will potentially lead to a better
understanding of how chlamydial effectors mediate bacterial entry into host cells. The clone will
then be used for creating Tarp mutants in Chlamydia trachomatis in order to determine if a
phenotype can be observed from introducing a second copy of Tarp into the bacterium.
Therefore, this study can be perceived as a “tool-building” step on the road heading towards
revealing the ways to knockout genes within Chlamydia trachomatis.
Another objective of this study is to highlight the importance of the unpublished work
completed in the past within my lab and how these results have played a great contributive factor
towards accomplishing my desired tasks and the projects to be pursued in the future. In this
paper, various significant experiments would be discussed, such as the impact of the creation of
truncated wild-type chlamydial plasmids, the developmental cycle of Chlamydia trachomatis
observed over time under the persistent exposure of antibiotics, and how actin nucleation
changes with respect to the interaction between actin and various forms of mutant TARP present.
These various projects have subsequently provided the stepping stones towards the success of
my study.
7

METHODS
The shuttle vector used in our studies was comprised of an Escherichia coli origin of
replication and the β-lactamase gene from pBR328, the entire C. trachomatis plasmid sequence,
and an Inc-D promoter that was originally used in past experiments to express DsRed and CAT
proteins. In this study, the Inc-D promoter, DsRed, and CAT genetic sequence were removed
from the chlamydial vector (Figure 3).

Figure 3. Shuttle Vector and Potential New Mutations Induced.
The C. trachomatis shuttle vector pCtSV.1 was adapted to allow for the expression of c-Myc tagged Tarp by
the tarP promoter (tarPp). In frame deletions were incorporated into the tarP gene to encode for g-actin
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binding domain (pCtSV.TarpΔABD) and f-actin binding domain (pCtSV.Tarp ΔFAB1&2) deletions
respectively.

The TARP promoter and TARP genetic sequence were amplified from pGEM-3Z using primers
carrying the sequence for the c-Myc tag epitope (Figure 4). The PCR product was used as the
insert and ligated to the vector afore mentioned. The new constructed plasmid was first
transformed into E.
coli (DH5α cells) and
selected

through

ampicillin resistance.
A

miniprep

performed

on

was
the

viable colonies and
the

plasmids

were

retrieved, confirmed,
and sequenced.
Figure 4. Plasmid for
Tarp promoter + Tarp
protein Amplification.
The C. trachomatis Tarp
effector genetic sequence along with the Tarp promoter will be amplified from a pre-designed pGEM3Z+9kbTARP plasmid. The insert will be incorporated into the pCtSV.1 shuttle vector and it will replace the
DsRed and CAT genes along with the IncD promoter.
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This newly, constructed TARP plasmid with an epitope tag was used as the template for creating
TARP mutants. Specific sequences were deleted in major TARP domains, in which past

Figure 5. TARP molecular structure and actin protein interactions of WT vs. mutants.
A. The wild-type TARP effector protein is divided into 3 major domains called the phosD, PRD, and ABD,
which is further separated into fibrous and globular actin binding domains. The molecular structure of
TARP mutants are shown in comparison to the WT sequence with specific domains removed. B. The TARP
protein expressed from each mutant are run on an SDS-PAGE and their size corresponds to the amount of
sequence that was removed from the original encoding sequence. Confirmation of the specific deletions of
each domain is done through the use of monoclonal AB that have an affinity for the particular domain that is
removed. C. The effects of WT TARP and mutant forms on the nucleation of actin. D. A shuttle vector was
created to coexpress the GFP and Tarp protein, along with other Tarp mutants as shown in image A. This
vector when transfected into Hela cells did indeed express both proteins. GFP fused Tarp appeared more
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clustered inside the cell. When actin AB are placed onto these cells (as shown in second column), the fibers
turned red and under the merged view it showed that even when the ABD was absent, actin was still
nucleated. This led to the discovery of G-actin and F-actin binding domains [4].

research has shown to possibly play a key role in host cell invasion. The domains that have been
noted for importance were the phosphorylation domain (phosD), proline domain (PRD), G-actin
binding domain (ABD), and the F-actin binding domains (FAB 1 and 2) (Figure 2, 5). As shown
in Figure 5, through extensive protein biochemical assays, TARP was implicated for playing an
important role in host cell actin nucleation. Most importantly, the coexpression of both GFP and
mutant TARP protein enabled for the presence of different actin binding domains to be
determined. Of the various domains, previously discussed, the first mutant TARP pursued was
the deletion within the phoshorylation domain. The mutant TARP insert was digested from a
previously created plasmid called the GSTRecA + His6 pGEX-6P-1 and was ligated to the
epitope tagged vector (Figure 6). Other TARP mutants could potentially be created through the
same process. The vector was transformed into DH5α cells in order to obtain a larger quantity of
the plasmids.
The plasmids retrieved from DH5α cells were then transformed into ER2925 cells in
order de-methylate the DNA and made them compatible in C. trachomatis. The retrieved and
confirmed plasmids were transformed into C. trachomatis for expression. An intriguing aspect of
the application of the new transformation system was that in our study we were able to select for
our specific transformant through the use of the penicillin resistance gene as the selectable
marker. Since the resistant gene was only present in the wild-type epitope-tagged and mutant
TARP plasmids, the only chlamydial pathogen that should survive were the bacteria that have
been successfully transformed and carried our vector.
11

Figure 6. Plasmid carrying the TARP mutant sequence in the phosphorylation domain.
A segment of the TARP sequence that carries the complete deletion of the phosphorylation domain was taken
from this plasmid. The digested insert later replaced the Phos domain sequence in the epitope-tagged
plasmid.

Another technology that has allowed for detection of the newly introduced genes within
the chlamydial system was antibodies that acted in ligand-protein interactions. An organized
protocol was laid out to distinguish the expressed protein of interest with great sensitivity. In
order to identify the protein, a primary antibody was used that carried strong affinity for the
protein and a secondary antibody was applied to detect the presence of the bound primary. In
12

order to visualize these interactions, a chemiluminescent substrate was added that has an affinity
for the secondary antibody. When exposed to UV radiation, the X-ray film would capture any
trace of ligand-protein interactions present.
This new protocol was applied to detect the expression of the epitope tagged Tarp protein
through the use of monoclonal antibodies that specifically recognized the c-Myc tag. In order to
determine the presence of epitope tagged Tarp effector, the collected proteins from lysed
Chlamydia were purified and separated on an SDS-PAGE protein gel. The protein gel was
transferred onto a membrane in order to perform a Western Blot and from that membrane the cMyc tag was detected with specialized antibodies that recognized the epitope. The initial primary
antibody used was a c-Myc 9E10 monoclonal antibody that bound to the epitope. Afterwards, a
secondary HRP conjugated antibody was applied that recognized the primary 9E10.

A

chemiluminescent substrate placed over the membrane produced light that was detected by X-ray
film that localized the presence of the tagged Tarp on the transferred membrane.

13

RESULTS
Creation of Epitope-Tagged Wild-type and Mutant TARP

The c-Myc tag epitope and phosphorylation domain deletion were successfully
introduced into the TARP shuttle vector. The presence of the epitope and absence of the PhosD
were confirmed through sequencing, digestion, and PCR verification, as shown in Figure 7 and
Figure 8 respectively.

Figure 7. Digestion and PCR confirmation of wild-type tagged TARP in retrieved plasmid.
Clones were retrieved from possible positive E. coli transformants that may carry the constructed vector with
the full length, tagged TARP sequence. The presence of the genetic sequence was confirmed through the
digestion of the mini-prep retrieved plasmid and PCR amplification using specific primers that recognized
the TARP promoter and c-Myc tag sequence.
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In Figure 7, the second and third lane are bands representing the exact size of the
chlamydial vector backbone and tagged-TARP insert that should be present if epitope-tagged
TARP was indeed successfully transformed into Escherichia coli. A closer look at Figure 7, the
fourth and fifth lanes show the relative size of two digested plasmids, labeled 5a and 5b, which
were retrieved from transformed ampicillin resistant E. coli clones. These two digestions were
each separated into two bands that lined up perfectly with the vector and insert in the previous
two lanes. Therefore, there is great possibility that these bands represent the segments in the
desired plasmid. The last 2 lanes display the PCR verification reactions in which the TARP
protein is amplified from the two clones. From this figure, it can be observed that TARP and the
epitope tag were successfully introduced with great certainty; sequencing confirmed their
presence and the reading frame was correct.

Figure 8. Digestion and PCR confirmation of mutant TARP from retrieved plasmids.
Clones were retrieved from possible, successful E. coli transformants that may carry the mutant-TARP
sequence with the phosphorylation domain removed. The plasmids purified from the clones through
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miniprep were digested with restriction enzymes specific for the beginning of the TARP promoter and
directly after the c-Myc tag. PCR amplification of the plasmids were also performed using primers that
recognized the promoter and epitope sequence.

In Figure 8, the second, third, and fourth lanes are the digestions of 3 plasmids retrieved
from potential E. coli transformants that may carry the PhosD TARP mutant sequence. In all 3
plasmids, the two bands that dropped out appeared to line up with one another which could
possibly mean that the 3 clones all carried the same plasmid. In the fifth lane is the digestion of
the original epitope-tagged plasmid from the former experiment with the two bands showing the
size of the wild-type tagged-TARP sequence and the chlamydial vector backbone. In the 3
former lanes, the larger band lined up with the fifth lane’s vector backbone but the inserts were
different in size as expected. The 3 former lanes showed a much smaller insert compared to the
fifth lane because the TARP sequence had the phosphorylation domain removed. As a result, the
insert in the wild-type epitope TARP is larger in size and appears higher on the DNA ladder. The
6th-8th lanes, on the other hand, are PCR reactions performed on the plasmids of the 3 clones. In
the image, for all 3 lanes, mutant TARP was amplified which matched the size of the digested
insert in lanes 2-4. In the last lane is the PCR amplification of wild-type TARP and the size of
the band is the same as the digested insert in lane 5.
The expression of the mutant TARP from the shuttle vector inside Chlamydia
trachomatis was determined through antibody-protein interactions. PhosD mutant TARP
expression was detected from the host-bacterial lysate. The result of the protein assay is found in
Figure 9. In the immunoblot image captured, the 4th lane shows anti-TARP antibody interaction
against the TARP protein expressed from the shuttle vector labeled L2+ pCTSV.TarpΔphos.
However, in this lane 2 bands were visible on the immunoblot because the Tarp antibody not
16

only detected the wild-type TARP expressed on Chlamydia’s genomic DNA but also the mutant
TARP expressed off of the engineered plasmid. This is most apparent when comparing the
tagged-mutant protein against the expression of the original genomic TARP (L2) and wild-type
shuttle vector TARP (L2+pCtSV.1) which shows only one band of Ag-AB interaction. Also,
when these latter samples and mutant TARP were exposed to anti-c-Myc AB, no bands appeared
for L2 and L2+pCtSV.1 because these proteins lacked the epitope tag. The mutant phosD TARP
(L2+ pCTSV. TarpΔphos) clone,
however, did show expression as
expected.
Figure 9. Detection of Tarp and c-Myc
protein expression with Tarp and c-Myc
AB.
The

protein

lysate

retrieved

from

Chlamydia-host infections were purified
and separated by SDS-PAGE. The gel
was transferred over to a membrane to
conduct ligand-protein binding assay
with TARP and c-Myc epitope acting as
the ligand for detection with their
respective monoclonal antibodies.
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Truncating the Wild-type Chlamydial Plasmid
One of the previous chlamydial projects that I have performed was devoted towards
creating deletions within the wild-type chlamydial plasmid found within the pathogen itself. The
purpose of the project was to truncate the bacterial plasmid to determine if the transformation
efficiency into E. coli and C. trachomatis could be improved. With such a large plasmid, it posed
as a restriction on the size of the foreign gene that can be introduced into the prokaryote.
Moreover, the results of transformation into the pathogen could reveal which segment within the
plasmid carried an important factor in the developmental cycle of the bacteria. Potentially, these
truncated plasmids could be used as the templates within chlamydial transformations instead of
employing the complete WT plasmid sequence as the vector backbone which is very large and
can hinder transformation efficiency.
The project was carried out by first starting out with a plasmid our lab has engineered
called pCtSV.1 (Figure 10). The shuttle vector possessed an IncD promoter that controlled the
expression of DsRed and CAT proteins and ligated to it was the complete chlamydial plasmid
sequence. The shuttle vector, therefore, served as the template and parts of the complete bacterial
sequence of different sizes were slowly taken away. As depicted in Figure 10, when the
truncated constructs were digested with the same restriction enzymes, the same vector backbone
is observed in all samples but the size of the insert that drops out varied depending on the amount
of DNA bases that have been removed from the chlamydial sequence.

18

Figure 10. DNA digestions of various truncated Chlamydial constructs.
The digestion observed above is the result of the truncations of the original chlamydial plasmid. The original
template (found in Figure 5) carried the complete bacterial sequence, an E. coli origin of replication, βlactamase gene, Inc D promoter, and genes encoding DsRed and CAT proteins. The E. coli origin of
replication (Ori) , as well as the inherent chlamydial Ori, allows for the plasmid to shuttle between two
different transformation systems. In this experiment, segments of the original chlamydial sequence were
slowly removed to form different size of plasmids to determine if transformation efficiency can be increased if
the size of the shuttle vector is reduced.

The 4000 base pair band observed in all five digestion reactions was the original backbone,
which carried the genetic sequence for the E. coli’s origin of replication, β-lactamase gene, IncD
promoter, as well as the DsRed and CAT genes. In the first plasmid, P1, retrieved from a
transformed clone, about 6,000 base pairs were removed from the chlamydial plasmid sequence.
Therefore, P1 carried an insert close in size to 1,000 base pairs. For clones P2 and P3, about
5,000 and 3,000 base pairs were removed respectively from the original 7,500 base pairs. Taking
19

a closer look at the P3 digestion reaction, the DNA gel shows a slight overlap to two DNA bands
which was expected because the vector backbone was similar in size to the chlamydial insert. In
clones P4 and P5, about 2,000 and 1,000 base pairs were removed respectively from the
template.
Creation of Antibiotic Resistant Chlamydia trachomatis

The plasmid pCtSV.1, a crucial shuttle vector employed within this study, was created
from a previous unpublished project which allowed for the DNA to have the ability to replicate
within Chlamydia trachomatis and Escherichia coli. Moreover, this plasmid provided the
antibiotic selectable marker, which was crucial in this project, through the organism’s growth
and resistance to ampicillin treatment. When this shuttle vector was shown to be successfully
replicated and expressed within E. coli, the plasmid was transformed into C. trachomatis and an
observable phenotype was recorded. The phenotype studied was progeny counts, based on the
presence of inclusion bodies. The assumption made in the study was that only one elementary
body (also called infectious units), with proper dilutions, would enter only one host cell and
create one inclusion body. Therefore, when cells lyse and new infections occur, the number of
EBs (IFUs) were determined indirectly through the number inclusion bodies that results after the
lysis.
In this project, two types of plasmids were used to transform into C. trachomatis which
included the shuttle vector pCtSV.1 and the wild-type plasmid originally found within the
pathogen. The developmental cycles of the two transformations were observed over a 102-hour
period under two separate conditions. As shown in Figure 11, the WT Chlamydia and
transformed pCtSV.1 clone were both treated with and without penicillin after they have infected
20

host cells. The effects on progeny counts were then determined through inclusion bodies count.
When the quantity of IFUs were recorded and plotted onto a logarithmic graph, the data
displayed that there was no significant changes in progeny counts between the pCtSV.1 clones
whether it was grown in the presence or absence of penicillin. The wild-type clone, however,
was not able to thrive and grow in the presence of penicillin because these clones did not possess
the β-lactamase gene. When the WT was grown in the absence of penicillin, on the other hand,
they grew rapidly in the same manner that was observed with the pCtSV.1 transformants.

Figure 11. C. trachomatis transformed with the chlamydial shuttle vector pCtSV.1 confers penicillin
resistance.
C. trachomatis LGV L2 (wild type: WT) was transformed with the chlamydial shuttle vector and a
transformed clone was isolated after multiple developmental cycles in the presence of penicillin (pCtSV.1).
The presence of the shuttle vector was confirmed following DNA isolation and recovery of the plasmid in E.
coli. The growth curve shown represents the infectious EBs (IFUs) recovered from McCoy cells infected with
our wild type (WT) and transformed clone (pCtSV.1) in the presence or absence of penicillin. EBs were
recovered every 6 hours from 24 to 102 hours post infection. The number of infectious EBs harvested was
determined by the introduction of recovered material to new McCoy cells and inclusions were counted after
24 hours.
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The presence of the inclusion bodies was visualized through the application of an
immunofluorescent assay (IFA). In this assay an anti-L2 EB antibody was used to bind to EBs
present within the inclusion bodies. A secondary antibody was then used to detect this primary
AB and the one used was Alexa 488 which allowed for visualization of EB’s at a particular
wavelength. The image in Figure 12 supports the idea that, under penicillin treatment, WT
cannot grow whereas the pCtSV.1 clone would not have any problems.

Figure 12. IFA of penicillin resistant C. trachomatis transformants.
C. trachomatis EBs were transformed with shuttle vector pCtSV.1 (+ DNA) or mock treated (- DNA)
according to the protocol developed by Dr. Ian Clarke [42]. One developmental cycle (one cycle equals
approximately 2 days) occurred in the absence of antibiotics followed with 4 developmental cycles (4
passages) in the presence of penicillin. For each passage, approximately 10% of the preparation was added to
a 24 well plate containing fresh McCoy cells and chlamydial inclusions were detected after 24 hours with an
anti-L2 EB antibody and Alexa 488 conjugated secondary antibody. No C. trachomatis inclusions were
detected from the mock transformed bacteria after two passages with penicillin.
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DISCUSSION
From the data gathered, it is evident that a model is now present with the potential of
introducing mutations into the chlamydial genomic DNA. Never before has a copy of an
endogenous gene been successfully tagged and expressed within the chlamydial system on a
separate plasmid. This leads the way towards enabling the Chlamydia scientific community to
gain one step closer towards creating a gene knockout within the pathogen and determining the
function of each gene. Not only can C. trachomatis now be tagged with a selectable marker
bound to a protein of interest but also selected through ampicillin resistance because it carries the
gene necessary to survive the antibiotic treatment.
The transformation with the delta Phos Tarp, in addition, has shown to have a greater
turnover rate in entering the bacterial pathogen which may implicate that this domain is not vital
to the invasion process of C. trachomatis. The deletion of this domain, on the contrary, may
enable the prokaryote to become more pathogenic. These speculations, however, need to be
furthered analyzed in future assays in contrast to the wild type Tarp to test its validity.
Another major contribution that this study has provided is the characterization of the Tarp
promoter sequence. In chlamydial literature the Tarp promoter has never been characterized;
therefore, the scientific community is still unaware of the size of the gene and how much of it is
necessary for initiation of transcription. With the success of having expression of Tarp and cmyc epitope off of the plasmid that I have created, implicates that 200 base pairs of the Tarp
promoter is sufficient for proper functioning. This promoter can now be employed in future
studies to express other mutant forms of Tarp as well as other desired foreign genes. Although
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my study focused primarily on the “tool-building” process, the success of this experiment is a
major stepping stone towards gaining a better understanding of the chlamydial genome. This
opens the path towards numerous possibilities to the future studies that may lie ahead.
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FUTURE STUDIES
My future endeavors are aimed at creating more mutant Tarp constructs, using the wildtype tagged Tarp clone as the template. For instance, after the success with deletion of the
phosphorylation domain, the other domains were left untouched. Therefore, mutations can still
be made in the PRD, ABD, and FAB as well as combinations of the different deletions (Figure
5). The mutant TARP will potentially be introduced into the genomic DNA through
recombination and the effects of a mutant gene can be observed through its phenotype. When a
gene is either removed or introduced into a genome, there may be unprecedented effects on the
organism’s pathogenicity, development, and viability. All of these various changes can be
tracked and studied through the use of invasion assays, developmental assays, and progeny
counts respectively. Since the tagged-effector TARP has been mutated, once it undergoes allelic
exchange with the genomic TARP, it is very likely that Chlamydia trachomatis may have a
diminished infectiousness, a retarded growth rate, and decreased amount of progeny. However,
these are only mere speculations that will require further experimentations to confirm their
accuracy.
Moreover, the truncated plasmids that were previously created in a past experiment could
be used for transforming the mutant Tarp with greater efficiency because a smaller plasmid
enters the pathogen at a faster rate. In addition, in a recent study performed by the Wayne State
University has provided some evidence that the transformation of Chlamydia trachomatis
compounded with dendromeres have the potential of increasing the success of introducing
foreign genes into the bacteria by 80%. This new method will be implemented in the near future
with my studies on transforming C. trachomatis with my new Tarp mutant genes.
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